NP-HPLC测定阿敏-额尔敦中士的宁的含量

目的:建立蒙药阿敏-额尔敦中士宁含量测定方法.方法:采用正相高效液相色谱法.色谱柱为JapanInertsil(SIL 100A-5μm,4.6mm×150mm),流动相为正己烷-二氯甲烷-甲醇-浓氨试液(47.5:47.5:5:0.35),流速1mL·min-1,柱温:30℃,检测波长为254nm.结果:士的宁进样量在0.0918～0.459μg范围内呈良好的线性关系(r=0.9996),平均加样回收率为98.12%,RSD为0.87%.结论:采用正相高效液相色谱法测定士宁含量,方法简便、灵敏、准确,可作为蒙药阿敏-额尔敦的质量控制方法.     

The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.

AIM: Serum tumour markers carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and CA242 were investigated to evaluate the values of single and combined test in the diagnosis and prognosis of pancreatic cancer. METHODS: Pre-operative serum CEA, CA19-9 and CA242 were measured in 105 pancreatic cancers, 70 non-pancreatic malignancies and 30 benign pancreatic diseases. RESULTS: The sensitivity of CA19-9 alone was the highest in pancreatic cancer patients (80%), but the specificity was significantly lower than that of CEA and CA242 (P<0.01). The combination of CEA and CA242 could increase the specificity to 92%. In serum CA242 positive patients, the survival time was remarkably shorter than that of patients with negative result (P<0.01). The survival time in patients with more than two markers positive expression of CEA, CA19-9 and CA242 was obviously shorter than that of only one or no marker positive expression (P<0.05). CONCLUSION: The diagnostic rate of CA19-9 in pancreatic cancer is better than that of CEA and CA242. Combined detection of CEA and CA242 can improve the diagnostic specificity obviously. High levels of serum markers are associated with advanced stage of the disease. Patients with two or three markers positive expression of CEA, CA19-9, and CA242 simultaneously had a shorter survival time.     

Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome.

PURPOSE: Preoperative chemoradiotherapy may increase the R0 (curative) resection rate, overall survival (OS) duration, and disease-free survival (DFS) duration. We evaluated paclitaxel-based induction chemotherapy and chemoradiotherapy in patients with localized gastric or gastroesophageal adenocarcinoma to determine its feasibility, impact on the R0 resection rate, type of pathologic response, OS, and DFS. PATIENTS AND METHODS: Patients with operable, localized gastric, or gastroesophageal adenocarcinoma were eligible. Staging included endoscopic ultrasonography (EUS) and laparoscopy. Patients received two 28-day cycles of induction chemotherapy of fluorouracil, paclitaxel, and cisplatin followed by 45 Gy of radiation and concurrent fluorouracil plus paclitaxel. The cancer was restaged and surgery was attempted. Postsurgery pathologic findings and R0 resection were correlated with OS and DFS. RESULTS: Forty-one patients were enrolled. Most carcinomas were proximal (83%) and pretreatment stage EUST3 (85%). Forty patients (98%) underwent surgery, and 78% had an R0 resection. We observed a pathologic complete response (pathCR) rate of 20% and a pathologic partial response (pathPR) rate of 15% (< 10% residual cancer cells in the resected specimen). No pretreatment parameter (sex, cancer location, baseline T stage, or baseline N stage) predicted the type of postsurgery pathologic response, OS, or DFS. However, pathCR (P = .02), pathCR + pathPR (P = .006), R0 resection (P < .001), and postsurgery T and N stages (P = .01 and P < .001, respectively) were associated with OS. Same parameters were significantly correlated with DFS. Toxicity was manageable. CONCLUSION: The type of pathologic response but not pretreatment parameters was associated with OS and DFS. Efforts to increase the rate of pathologic response and better systemic cancer control are warranted.     

Polymorphisms in XPD exons 10 and 23 and bladder cancer risk.

INTRODUCTION: The nucleotide excision repair gene, xeroderma pigmentosum complementation group D (XPD), has been hypothesized to have a role in cancer risk, but results from prior molecular epidemiologic studies and genotype-phenotype analyses are conflicting. MATERIALS AND METHODS: We examined the frequency of the XPD Asp312Asn polymorphism in exon 10 and the XPD Lys751Gln polymorphism in exon 23 in 505 incident bladder cancer cases and 486 healthy controls. RESULTS: Overall, the XPD exon 10 and 23 genotypes were not associated with bladder cancer risk, after adjusting for age, sex, ethnicity, and smoking status. A gender-specific role was evident that showed an increased risk for women, but not for men, associated with the variant genotypes for both exons. For example, when the exon 23 variant allele genotypes were combined (Lys/Gln + Gln/Gln), there was an increased bladder cancer risk in women [odds ratio (OR), 1.69; 95% confidence interval (95% CI), 1.12-2.58] but not in men (OR, 0.99; 95% CI, 0.79-1.24; P(interaction) = 0.041; OR, 1.62; 95% CI, 1.02-2.58). There was also a gene-smoking interaction that showed the variant alleles for either exon or the combination of both increase the risk of bladder cancer for light and heavy smokers. For exon 23 (P(interaction) = 0.057; OR, 1.21; 95% CI, 0.99-1.47), heavy smokers (> or = 20 pack-years) who carried the exon 23 variant allele genotypes had an OR of 4.13 (95% CI, 2.53-6.73), whereas heavy smokers with the wild-type genotypes were at lower risk (OR, 3.55; 95% CI, 2.19-5.75). Moderate smokers (1-19 pack-years) with the variant allele genotypes had an OR of 1.54 (95% CI, 0.94-2.53), whereas moderate smokers with the wild-type genotypes had an OR of 1.12 (95% CI, 0.63-1.98). CONCLUSIONS: Although we did not observe main effects associated with the XPD genotypes, these results do suggest the variant allele genotypes were associated with increased bladder cancer risk in women and smokers with statistically significant interactions in the exon 23 polymorphism. Although there is biological plausibility, these novel findings for gender and smoking should be interpreted with caution upon confirmation in larger studies.     

Al互连线微结构的EBSD分析与电徙动可靠性

采用电子背散射衍射技术(EBSD),测量了微电子器件中Al互连线的晶粒结构、晶体学取向和晶界特征.Al互连线制备及退火工艺影响着互连线的显微结构和电徙动中值寿命(MTF).结果表明,退火后晶粒明显长大,晶粒呈近竹节结构,形成很强的{111}织构,并使小角度晶界增加,从而提高了Al互连线的电徙动可靠性.     

食管癌发生发展过程中TRAIL和Survivin蛋白的表达研究

目的探讨食管癌发生发展过程中TRAIL、Survivin蛋白的表达及与食管癌病理特征的关系。方法采用免疫组化SP法对60例食管癌手术后大体标本中食管正常黏膜、单纯增生、不典型增生及浸润癌组织进行检测及分析。结果TRAIL蛋白从正常黏膜一单纯增生一不典型增生一浸润癌呈渐进性低表达，而Survivin蛋白则呈渐进性高表达。食管浸润癌组织中TRAIL蛋白的低表达与Survivin蛋白的高表达呈负相关（r=-0．480，P〈0．01）。结论TRAIL和Survivin2种蛋白参与了食管癌的发生发展，两者的表达失调导致了食管癌的发生。     

S100A4蛋白在宫颈鳞癌中的表达及意义

目的　研究S10 0A4蛋白在宫颈鳞癌组织中的表达及其临床意义。方法　应用免疫组织化学SP法检测 65例宫颈鳞癌组织和10例正常宫颈组织中S10 0A4蛋白。结果　在正常宫颈组织中S10 0A4蛋白不表达 ;在宫颈鳞癌组织中S10 0A4蛋白的表达率为3 5 .4% ( 2 3 /65 ) ;与正常宫颈组织比较 ,差异具有显著性 (P <0 .0 1)。S10 0A4蛋白在宫颈鳞癌中的表达与临床分期和淋巴结转移有关 (P <0 .0 1) ,与组织学分级无关 (P >0 .0 5 ) ;阳性细胞在血管平滑肌细胞以及淋巴细胞中亦有表达。结论　S10 0A4蛋白和宫颈鳞癌的侵袭和转移密切相关 ;S10 0A4蛋白可作为判定宫颈鳞癌临床病理特征的重要指标     

Bcl-2反义寡核苷酸对裸鼠人肺癌移植瘤抑制作用的研究

目的探讨Bcl-2反义寡核核苷酸(ASODN)对裸鼠人肺癌移植瘤的成瘤能力和生长的抑制作用。方法将经硫代修饰的Bcl-2ASODN导入非小细胞肺癌。NCI-H460细胞内,然后将这种细胞接种于裸鼠皮下,观察肿瘤出现的时间和肿瘤体积的变化,并计算抑瘤率。同时采用未经处理的NCI-H460细胞接种于裸鼠背部皮下建立裸鼠人肺癌移植瘤模型,待长出瘤结节直径为≥5mm后,分为Bcl-2ASODN实验组、生理盐水对照组和无义寡核苷酸对照组3组。实验组用15mg/kgASODN两天一次直接瘤内注射,连用3周,测肿瘤大小变化和组织形态学改变。结果Bcl-2ASODN作用后的NCI-H460细胞在裸鼠皮下成瘤能力降低,最大抑瘤率达87.5%(P相似文献   

中华眼镜蛇毒组分C与几种临床化疗药体外对人胶质瘤株作用的差异研究

背景与目的：脑胶质瘤是常见的颅内肿瘤，占脑恶性肿瘤的50％以上，化疗作为综合治疗的一项重要手段，仍存在效果不理想、易耐药等问题。本文就研究中华眼镜蛇毒组分C（Fraction C from Naja Naja Actra Venom，NNAV．FC）体外对人胶质瘤细胞株U-251的细胞毒性作用，并与几种临床脑肿瘤化疗用药进行比较，以求为脑胶质瘤的治疗提供新的化疗药物。方法：应用MTT法．观察NNAV．FC人胶质细胞瘤株U-251的细胞毒作用、量效关系等，并与依托泊苷（vp=16、鬼臼乙叉苷、Vepesid）、卫萌（替尼泊苷、鬼臼甲叉甙vm-26，Teniposide）、顺铂（Cisplatin、CDDP）、卡铂（Carboplatin）、五氟尿嘧啶（5-FU）等对上述细胞的细胞毒作用进行比较。结果：FC对人胶质瘤细胞有明显的抑制作用，其24及48h的IC50分别为5．76和7．19μg／ml，且呈良好的量效关系。结论：在本实验中，FC能有效抑制胶质瘤细胞株的生长，抑制作用与浓度呈正相关，与临床胶质瘤化疗药相比较。FC是有效地抑制胶质瘤细胞生长的药物。     

前纵裂入路切除鞍区巨大肿瘤

背景与目的：鞍区巨大肿瘤手术难度较大，本文探索前纵裂入路切除鞍内、鞍上向单双侧海绵窦、第三脑室、蝶窦及伴颞叶发展的巨大肿瘤的手术适应症、方法与优缺点方法：总结分析2002年1月至2004年5月我科经前纵裂入路切除鞍区各部位发展的肿瘤17例。结果：肿瘤全切14例，近全切2例．部分切除1例；术后视力改善12例，无改变5例，尿崩或电解质紊乱8例，死亡1例，随访时间3～32个月，有1例复发，系巨大侵袭性垂体瘤术后，行γ-刀治疗后肿瘤基本得到控制。结论：前纵裂入路是切除鞍内、鞍上向单双侧海绵安、第三脑室、蝶窦及伴颞叶发展的肿瘤较理想的入路，利用自然脑裂的分离，手术视野、操作角度好、肓区少，有利于显露重要血管、神经及双侧海绵窦内侧壁，肿瘤全切率高。